Skip Navigation LinksHome > May 1, 2007 - Volume 45 - Issue 1 > Early Virologic Failure in HIV-Coinfected Hepatitis C Patien...
JAIDS Journal of Acquired Immune Deficiency Syndromes:
doi: 10.1097/QAI.0b013e318040b2b6
Letters to the Editor

Early Virologic Failure in HIV-Coinfected Hepatitis C Patients Treated With the Peginterferon-Ribavirin Combination: Does Abacavir Play a Role?

Bani-Sadr, Firouzé MD*; Denoeud, Lise MD*; Morand, Patrice MD, PhD†; Lunel-Fabiani, Françoise MD, PhD‡; Pol, Stanislas MD, PhD§; Cacoub, Patrice MD∥; Perronne, Christian MD, PhD¶; Carrat, Fabrice MD, PhD*; Agence Nationale pour la Recherche contre le SIDA et les hépatites virales HC02-Ribavic Study Team

Free Access

To the Editor:

HIV coinfection increases the percentage of patients who show hepatitis C virus (HCV) RNA declines of <2 logs at 12 weeks of peginterferon (pegIFN) and ribavirin combination therapy to 29% to 33%.1,2 We wanted to identify baseline host-related or virus-related factors that might predict early virologic failure of pegIFN α-2b plus ribavirin therapy in patients coinfected with HIV and HCV.

The results of the French National Agency for Research on AIDS and Viral Hepatitis (ANRS) HC02-Ribavic Study have been reported elsewhere.1 In brief, 206 of 416 HIV/HCV-coinfected patients who had never received interferon or ribavirin were randomly assigned to receive weekly subcutaneous injections of 1.5 μg/kg of pegIFN α-2b (ViraferonPeg; Schering-Plough, Kenilworth, NJ) plus 800 mg/d of ribavirin for 48 weeks, and 210 patients were randomly assigned to receive thrice-weekly subcutaneous injections of 3 megaunits of interferon α-2b plus 800 mg/d of ribavirin for 48 weeks. Only patients treated with pegIFN α-2b plus ribavirin and who had taken at least 80% of the total prescribed dose regimen were analyzed here. Early virologic responses were defined by undetectable serum HCV RNA in a qualitative polymerase chain reaction (PCR) assay (Amplicor 2.0 HCV Monitor, detection limit of 50 IU/mL; Roche Diagnostics Systems, Pleasanton, CA) or a decrease of more than 2 log10 in serum HCV RNA in a quantitative PCR assay (bDNA3.0, detection limit of 615 IU/mL; Bayer Diagnostics, Tarrytown, NY) at week 12. We used the χ2 test or Fisher exact test to analyze qualitative variables and the Mann-Whitney test to analyze quantitative variables. Logistic regression models were used to test possible associations between nonresponse (outcome variable) and pretreatment characteristics (input variables). Characteristics with P < 0.10 in univariate analysis were included in multivariate models based on a backward elimination procedure. All statistical tests were 2-sided, with a type I error of 5%.

A total of 194 patients received at least 1 dose of pegIFN α-2b plus ribavirin, and 154 of these patients received at least 80% of their study medication during the first 12 weeks of treatment. Fifty-seven patients (37%) did not have an early HCV virologic response; their mean decline in HCV viral load during the first 12 weeks of treatment was 0.6 ± 0.6 log10 IU/mL. We analyzed the clinical and virologic data to identify baseline factors that were predictive of early HCV virologic failure. Univariate analysis identified higher HCV viral load, genotype 1 or 4 infection, abacavir-based antiretroviral therapy, and elevated gamma-glutamyl transferase (GGT) and bilirubin levels (Table 1). In multivariate analysis, elevated baseline HCV viral load, HCV genotype 1 or 4 infection, abacavir-based antiretroviral therapy, and an elevated baseline bilirubin level remained significantly associated with the risk of early HCV virologic failure (see Table 1).

Table 1
Table 1
Image Tools

Because HCV genotype 1 or 4 infection was the most influential risk factor for early virologic failure, we repeated the analyses in the subgroup of patients infected by these genotypes. In multivariate analysis, abacavir-based antiretroviral therapy (odds ratio [OR] = 4.15, 95% confidence interval [CI]: 1.14 to 15.13; P = 0.031) and an elevated baseline bilirubin level (OR = 5.2, 95% CI: 1.34 to 20.36; P = 0.017) remained significantly associated with the risk of early virologic failure.

Several patient-related and virus-related factors have been shown to influence the response to optimal interferon-ribavirin combination therapy for HCV infection.1-4 Most studies compared patients with sustained virologic responses and those with virologic relapse or no response. Nonresponders differ from patients who relapse, in whom HCV RNA becomes undetectable during treatment but then reappears on treatment withdrawal. In nonresponder HCV-monoinfected patients, the average drop in HCV viral load at week 12 is 1 log10, with no subsequent decline during continued treatment.3 Our study confirms that a high baseline HCV viral load and HCV genotype 1 or 4 infection are the most important baseline predictors of early virologic failure.

The link found here between the risk of early nonresponse to anti-HCV therapy and abacavir exposure was unexpected and points to a possible role of drug interaction. In multivariate analysis, concomitant treatment with abacavir and pegIFN-ribavirin was associated with an adjusted 4.9-fold increase in the risk of nonresponse to anti-HCV therapy. The only significant differences between abacavir-treated and abacavir-untreated patients were a longer duration of antiretroviral therapy and a higher baseline GGT level in abacavir-treated patients. These factors were considered in multivariate analysis, and therefore cannot explain the effect of abacavir after adjustment. Poor HIV virologic responses were recently reported with triple-nucleoside reverse transcriptase inhibitor (NRTI) regimens consisting of tenofovir plus another purine NRTI (abacavir or didanosine), but there was no evidence of plasma pharmacokinetic or intracellular phosphorylation interactions.5-7

Ribavirin is a purine ribonucleoside analogue used to treat hepatitis. In HIV/HCV-coinfected patients treated for both infections, ribavirin can affect intracellular NRTI levels by inhibiting inosine 5′-monophosphate dehydrogenase. In vitro, the level antagonism on HIV is lower when ribavirin is combined with abacavir rather than with stavudine or zidovudine.8 The potential loss of ribavirin efficacy on HCV during concomitant use of these NRTIs has not previously been reported, however.

The only host factor predictive of early HCV virologic failure in our study was an elevated serum bilirubin level at baseline. The pathophysiology of bilirubin elevation in this setting is not known, although a correlation between serum bilirubin and hepatic fibrosis is well established. Other factors known to have a negative influence on anti-HCV therapeutic outcome, such as older age, higher body mass index, advanced fibrosis or cirrhosis, liver steatosis, and the daily dose of ribavirin (12.2 mg/kg on average in our study), were not associated with early virologic failure in our study.3,4 Only 5 patients were from sub-Saharan Africa, and the possible impact of ethnicity on the virologic response could not therefore be evaluated.

If confirmed, the negative interaction observed here between ribavirin and abacavir on the response to anti-HCV therapy has to be taken into account in clinical practice.

Back to Top | Article Outline

ACKNOWLEDGMENTS

This study received financial support from ANRS Essai HC 02 and SIDACTION. Results are to be presented at the 14th Conference on Retroviruses and Opportunistic Infections (CROI 2007), Los Angeles, CA, February 25-28, 2007.

Firouzé Bani-Sadr, MD*

Lise Denoeud, MD*

Patrice Morand, MD, PhD†

Françoise Lunel-Fabiani, MD, PhD‡

Stanislas Pol, MD, PhD§

Patrice Cacoub, MD∥

Christian Perronne, MD, PhD¶

Fabrice Carrat, MD, PhD*

Agence Nationale pour la Recherche contre le SIDA et les hépatites virales HC02-Ribavic Study Team

*Groupe Hospitalier Universitaire Est Université Paris 6, INSERM U707 Paris, France

†Centre Hospitalier Universitaire Grenoble, France

‡Faculté de medicine Angers, France

§Groupe Hospitalier Universitaire Ouest Université Paris 5, INSERM U370 Paris, France

∥Groupe Hospitalier Universitaire Est Université Paris 6, UMR7087 Paris, France

¶Centre Hospitalier Universitaire Raymond Poincaré Université de Versailles Garches, France

Back to Top | Article Outline

REFERENCES

1. Carrat F, Bani-Sadr F, Pol S, et al. Pegylated interferon alfa-2b versus standard interferon alfa-2b, plus ribavirin for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA. 2004;292:2839-2848.

2. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med. 2004;351:438-450.

3. Di Bisceglie AM, Fan X, Chambers T, et al. Pharmacokinetics, pharmacodynamics, and hepatitis C viral kinetics during antiviral therapy: the null responder. J Med Virol. 2006;78:446-451.

4. Akuta N, Suzuki F, Sezaki H, et al. Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load. J Med Virol. 2006;78:83-90.

5. Gallant JE, Rodriguez AE, Weinberg WG, et al. Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects. J Infect Dis. 2005;192:1921-1930.

6. Hawkins T, Veikley W, St. Claire RL III, et al. Intracellular pharmacokinetics of tenofovir diphosphate, carbovir triphosphate, and lamivudine triphosphate in patients receiving triple-nucleoside regimens. J Acquir Immune Defic Syndr. 2005;39:406-411.

7. Kakuda TN, Anderson PL, Becker SL. CD4 cell decline with didanosine and tenofovir and failure of triple nucleoside/nucleotide regimens may be related. AIDS. 2004;18:2442-2444.

8. Margot NA, Miller MD. In vitro combination studies of tenofovir and other nucleoside analogues with ribavirin against HIV-1. Antivir Ther. 2005;10:343-348.

Cited By:

This article has been cited 35 time(s).

Antiviral Therapy
Differences in virological response to pegylated interferon and ribavirin between hepatitis C virus (HCV)-monoinfected and HCV-HIV-coinfected patients
Tural, C; Galeras, JA; Planas, R; Coll, S; Sirera, G; Gimenez, D; Salas, A; Rey-Joly, C; Cirera, I; Marquez, C; Tor, J; Videla, S; Garcia-Retortillo, M; Clotet, B; Sola, R
Antiviral Therapy, 13(8): 1047-1055.

Haemophilia
HCV treatment with pegylated interferon and ribavirin in patients with haemophilia and HIV/HCV co-infection
Denholm, JT; Wright, EJ; Street, A; Sasadeusz, JJ
Haemophilia, 15(2): 538-543.
10.1111/j.1365-2516.2009.01972.x
CrossRef
Gastroenterologie Clinique Et Biologique
ANRS HC 02 RIBAVIC: From multicenter trial to daily practice. Conclusions
Pol, S
Gastroenterologie Clinique Et Biologique, 33(): S118-S119.

Hiv Medicine
British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008
Gazzard, BG
Hiv Medicine, 9(8): 563-608.
10.1111/j.1468-1293.2008.00636.x
CrossRef
Journal of Viral Hepatitis
Epidemiology of hepatitis C virus infection in HIV-infected individuals
Thomson, EC; Main, J
Journal of Viral Hepatitis, 15(): 773-781.
10.1111/j.1365-2893.2008.00981.x
CrossRef
Hiv Medicine
British HIV Association guidelines for the management of coinfection with HIV-1 and hepatitis B or C virus 2010
Brook, G; Main, J; Nelson, M; Bhagani, S; Wilkins, E; Leen, C; Fisher, M; Gilleece, Y; Gilson, R; Freedman, A; Kulasegaram, R; Agarwal, K; Sabin, C; Deacon, C
Hiv Medicine, 11(1): 1-30.
10.1111/j.1468-1293.2009.00781.x
CrossRef
Scandinavian Journal of Infectious Diseases
Treatment of hepatitis C virus infection: Updated Swedish Consensus recommendations
Lagging, M; Wejstal, R; Uhnoo, I; Gerden, B; Fischler, B; Friman, S; Josephson, F; Karlstrom, O; Sangfelt, P; Schvarz, R; Weiland, O
Scandinavian Journal of Infectious Diseases, 41(): 389-402.
10.1080/00365540902998271
CrossRef
European Journal of Medical Research
The Influence of Haart on the Efficacy and Safety of Pegylated Interferon and Ribavirin Therapy for the Treatment of Chronic Hcv Infection in Hiv-Positive Individuals
Vogel, M; Ahlenstiel, G; Hintsche, B; Fenske, S; Trein, A; Lutz, T; Schurmann, D; Stephan, C; Khaykin, P; Bickel, M; Mayr, C; Baumgarten, A; Buggisch, P; Klinker, H; John, C; Golz, J; Staszewski, S; Rockstroh, JK
European Journal of Medical Research, 15(3): 102-111.

Gastroenterologie Clinique Et Biologique
ANRS HC 02 RIBAVIC: From multicenter trial to daily practice
Pol, S
Gastroenterologie Clinique Et Biologique, 33(): S91-S93.

Antiviral Therapy
The influence of abacavir and other antiretroviral agents on virological response to HCV therapy among antiretroviral-treated HIV-infected patients
Amorosa, VK; Slim, J; Mounzer, K; Bruno, C; Hoffman-Terry, M; Dorey-Stein, Z; Ferrara, T; Kostman, JR; Lo Re, V
Antiviral Therapy, 15(1): 91-99.
10.3851/IMP1492
CrossRef
Revista Chilena De Infectologia
Clinical guide HIV/AIDS acquired immunodeficiency syndrome
[Anon]
Revista Chilena De Infectologia, 27(3): 239-276.

Journal of Antimicrobial Chemotherapy
Efficacy of pegylated interferon plus ribavirin treatment in HIV/hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backbone
Mira, JA; Lopez-Cortes, LF; Barreiro, P; Tural, C; Torres-Tortosa, M; Gil, ID; Martin-Rico, P; Rios-Villegas, MJ; Hernandez-Burruezo, JJ; Merino, D; Lopez-Ruz, MA; Rivero, A; Munoz, L; Gonzalez-Serrano, M; Collado, A; Macias, J; Viciana, P; Soriano, V; Pineda, JA
Journal of Antimicrobial Chemotherapy, 62(6): 1365-1373.
10.1093/jac/dkn420
CrossRef
Gastroenterologie Clinique Et Biologique
Treatment of chronic hepatitis C in HIV-infected patients
Bani-Sadr, F
Gastroenterologie Clinique Et Biologique, 33(): S97-S103.

Expert Opinion on Pharmacotherapy
Drug interactions in the management of HIV infection: an update
Robertson, SM; Penzak, SR; Paut, A
Expert Opinion on Pharmacotherapy, 8(): 2947-2963.
10.1517/14656566.8.17.2947
CrossRef
Antiviral Therapy
Early monitoring of ribavirin serum concentration is not useful to optimize hepatitis C virus treatment in HIV-coinfected patients
Crespo, M; Pou, L; Esteban, JI; Falco, V; Ribera, E; Lopez, R; Sauleda, S; Curran, A; del Saz, SV; Feijoo, M; Ocana, I; Pahissa, A
Antiviral Therapy, 12(8): 1217-1223.

Hiv Medicine
European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults
Rockstroh, JK; Bhagani, S; Benhamou, Y; Bruno, R; Mauss, S; Peters, L; Puoti, M; Soriano, V; Tural, C
Hiv Medicine, 9(2): 82-88.
10.1111/j.1468-1293.2007.00535.x
CrossRef
Advances in Therapy
Abacavir/Lamivudine Fixed-Dose Combination Antiretroviral Therapy for the Treatment of HIV
Achenbach, CJ; Scarsi, KK; Murphy, RL
Advances in Therapy, 27(1): 1-16.
10.1007/s12325-010-0006-9
CrossRef
Journal of Antimicrobial Chemotherapy
Influence of concomitant antiretroviral therapy on the rate of sustained virological response to pegylated interferon plus ribavirin in hepatitis C virus/HIV-coinfected patients
Pineda, JA; Mira, JA; Gil, ID; Valera-Bestard, B; Rivero, A; Merino, D; Giron-Gonzalez, JA; Rios-Villegas, MJ; Gonzalez-Serrano, M; Collado, A; Garcia-Garcia, JA; Carrillo-Gomez, R; Lopez-Cortes, LF; Gomez-Mateos, J
Journal of Antimicrobial Chemotherapy, 60(6): 1347-1354.
10.1093/jac/dkm373
CrossRef
Clinical Infectious Diseases
Management of chronic hepatitis C virus infection in HIV-infected patients
Pol, S; Soriano, V
Clinical Infectious Diseases, 47(1): 94-101.
10.1086/588669
CrossRef
Expert Review of Anti-Infective Therapy
Pegylated IFN-alpha(2b) plus ribavirin for treatment-naive patients coinfected with HCV and HIV
Mallolas, J; Laguno, M
Expert Review of Anti-Infective Therapy, 6(3): 281-289.
10.1586/14787210.6.3.281
CrossRef
Journal of Medical Virology
Serum concentrations of ribavirin and pegylated interferon and viral responses in patients infected with HIV and HCV
Nicot, F; Legrand-Abravanel, F; Lafont, T; Dubois, M; Saune, K; Pasquier, C; Chatelut, E; Izopet, J
Journal of Medical Virology, 80(9): 1523-1529.
10.1002/jmv.21227
CrossRef
Clinics in Liver Disease
Management Complexities of HIV/Hepatitis C Virus Coinfection in the Twenty-First Century
Lo Re, V; Kostman, JR; Amorosa, VK
Clinics in Liver Disease, 12(3): 587-+.
10.1016/j.cld.2008.03.009
CrossRef
Journal of Antimicrobial Chemotherapy
New directly acting antivirals for hepatitis C: potential for interaction with antiretrovirals
Seden, K; Back, D; Khoo, S
Journal of Antimicrobial Chemotherapy, 65(6): 1079-1085.
10.1093/jac/dkq086
CrossRef
Hiv Medicine
Initiatives for developing and comparing genotype interpretation systems: external validation of existing rule-based interpretation systems for abacavir against virological response
Cozzi-Lepri, A
Hiv Medicine, 9(1): 27-40.

AIDS
Serum alpha-fetoprotein predicts virologic response to Hepatitis C treatment in HIV coinfected patients
Carrat, F; Bedossa, P; Lunel-Fabiani, F; Morand, P; Pialoux, G; Piroth, L; Salmon-Ceron, D; Bani-Sadr, F; Perronne, C; Cacoub, P; Pol, S
AIDS, 22(): 1513-1515.

Deutsche Medizinische Wochenschrift
HIV and hepatitis C co-infection
Vogel, M; Boesecke, C; Wasmuth, JC; Rockstroh, JK
Deutsche Medizinische Wochenschrift, 135(): 1186-1191.
10.1055/s-0030-1255129
CrossRef
Antiviral Therapy
Low response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C treated with abacavir
Vispo, E; Barreiro, P; Pineda, JA; Mira, JA; Maida, I; Martin-Carbonero, L; Rodriguez-Novoa, S; Santos, I; Lopez-Cortes, LF; Merino, D; Rivero, A; Soriano, V
Antiviral Therapy, 13(3): 429-437.

European Journal of Medical Research
The Treatment of Chronic Hepatitis C Virus Infection in Hiv Co-Infection
Vogel, M; Rockstroh, JK
European Journal of Medical Research, 14(): 507-515.

Antimicrobial Agents and Chemotherapy
Plasma Ribavirin Trough Concentrations at Week 4 Predict Hepatitis C Virus (HCV) Relapse in HIV-HCV-Coinfected Patients Treated for Chronic Hepatitis C
Morello, J; Soriano, V; Barreiro, P; Medrano, J; Madejon, A; Gonzalez-Pardo, G; Jimenez-Nacher, I; Gonzalez-Lahoz, J; Rodriguez-Novoa, S
Antimicrobial Agents and Chemotherapy, 54(4): 1647-1649.
10.1128/AAC.01399-09
CrossRef
AIDS Reviews
Update on the treatment of chronic hepatitis C in HIV-infected patients
Soriano, V; Barreiro, P; Martin-Carbonero, L; Vispo, E; Garcia-Samaniego, J; Labarga, P; Gonzalez-Lahoz, J
AIDS Reviews, 9(2): 99-113.

Journal of Virology
Coinfection with Hepatitis C Virus and Human Immunodeficiency Virus: Virological, Immunological, and Clinical Outcomes
Rotman, Y; Liang, TJ
Journal of Virology, 83(): 7366-7374.
10.1128/JVI.00191-09
CrossRef
Zeitschrift Fur Gastroenterologie
Prophylaxis, Diagnosis and Therapy of Hepatitis C Virus (HCV) Infection: The German Guidelines on the Management of HCV Infection
Sarrazin, C; Berg, T; Ross, RS; Schirmacher, P; Wedemeyer, H; Neumann, U; Schmidt, HHJ; Spengler, U; Wirth, S; Kessler, HH; Peck-Radosavljevic, M; Ferenci, P; Vogel, W; Moradpour, D; Heim, M; Cornberg, M; Protzer, U; Manns, MP; Fleig, WE; Dollinger, MM; Zeuzem, S
Zeitschrift Fur Gastroenterologie, 48(2): 289-351.
10.1055/s-0028-1110008
CrossRef
Antiviral Research
Viral hepatitis and HIV co-infection
Soriano, V; Vispo, E; Labarga, P; Medrano, J; Barreiro, P
Antiviral Research, 85(1): 303-315.
10.1016/j.antiviral.2009.10.021
CrossRef
Journal of Antimicrobial Chemotherapy
Usefulness of monitoring ribavirin plasma concentrations to improve treatment response in patients with chronic hepatitis C
Morello, J; Rodriguez-Novoa, S; Jimenez-Nacher, I; Soriano, V
Journal of Antimicrobial Chemotherapy, 62(6): 1174-1180.
10.1093/jac/dkn421
CrossRef
Clinical Infectious Diseases
What the Infectious Disease Physician Needs to Know About Pegylated Interferon and Ribavirin
Gara, N; Ghany, MG
Clinical Infectious Diseases, 56(): 1629-1636.
10.1093/cid/cit074
CrossRef
Back to Top | Article Outline

© 2007 Lippincott Williams & Wilkins, Inc.

Login